



Dr. med. Laure Thouvenin

Oncologie Médicale
Médecine Interne Générale

Lingue

FR,EN

Formazione

| | |
|-----------|---|
| dal 2024 | Participation in the <i>certificate of advanced studies</i> (CAS) "Integrative and complementary medicine in hospitals and the community" |
| 2023 | FMH title of specialist in internal medicine |
| 2021 | FMH title of specialist in medical oncology |
| 2006–2012 | Geneva University of Medicine, federal diploma in medicine |

Esperienze professionali

| | |
|-----------|--|
| 2021–2024 | Senior consultant in the medical oncology department of the University Hospitals of Geneva (inpatient, outpatient) |
| 2016–2021 | Outpatient medical oncology (Geneva University Hospitals), including one year in clinical research (research unit of the Dr Henri Dubois-Ferrière Dinu Lipatti Foundation) |
| 2012–2016 | General internal medicine (Hôpital de la Tour, then University Hospitals of Geneva) (in-hospital, emergency, intensive care) |

Appartenenze

- European Society for Medical Oncology (ESMO)
- Association Suisse des Médecins (FMH) (en cours)
- Association des Médecins du canton de Genève (AMGe) (en cours)
- Société Suisse d'Oncologie Médicale (SSOM) (en cours)

Pubblicazioni

Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland. [S Colomer-Lahiguera](#), [C Canella](#), [S Giacomini](#), [K Lê Van](#), [C Pedrazzani](#), [M Naegele](#), [L Thouvenin](#), [A O'Meara Stern](#), [R Condorelli](#), [T Corbière](#), [C Witt](#), [M Eicher](#), [K Ribl](#). Support Care Cancer. 2023 Jun 22;31(7):410. doi: 10.1007/s00520-023-07871-8.

[Differential impact of tamoxifen and aromatase inhibitors on thrombin generation : the prospective HEMOBREAST cohort](#). Blondon M, Bodmer A, Thouvenin L, Lecompte T, Righini M, Fontana P, Casini A. Blood Adv. 2022 May 10;6(9):2884-2892. doi: 10.1182/bloodadvances.2021006623

[Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.](#) Thouvenin L, Charrier M, Clement S, Christinat Y, Tille JC, Frigeri M, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P. Gynecol Oncol Rep. 2021 May 19;37:100787. doi: 10.1016/j.gore.2021.100787. eCollection 2021 Aug

[Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis : a case-series and narrative review.](#) Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Ther Adv Drug Saf. 2021 Mar 29;12:20420986211004745. doi: 10.1177/20420986211004745. eCollection 2021

[A new hope in the treatment of hepatocellular carcinoma.](#) Thouvenin L, Friedlaender A. Rev Med Suisse. 2020 May 27;16(695):1074-1078

[Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.](#) Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P. Cancer Biol Ther. 2020;21(3):197-202. doi: 10.1080/15384047.2019.1685291. Epub 2019 Nov 10

[Monoclonal gammopathies: from MGUS to multiple myeloma.](#) Thouvenin L, Lang N. Rev Med Suisse. 2019 May 15;15(651):1022-1026

Accreditamento

[Clinique Générale-Beaulieu](#)

Specialità

[Oncologia](#)

[Medicina interna](#)

Contatto

Générale-Beaulieu Swiss Oncology Network

Chemin de Beau-Soleil 20

1206 Genève

T 022 839 57 00

cabinet.thouvenin@beaulieu.ch

[Scaricare vCard](#)